A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Sapanisertib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.
- 17 Jun 2017 Planned initiation date changed from 14 May 2017 to 1 Aug 2017.
- 26 Apr 2017 Planned initiation date changed from 14 Apr 2017 to 14 May 2017.